Association Between Serum Myostatin Levels, Hospital Mortality, and Muscle Mass and Strength Following ST-Elevation Myocardial Infarction

Oliveira, Paula Gabriela Sousa de; Schwed, Juliana F.; Chiuso-Minicucci, Fernanda; Duarte, Sara R.S.; Nascimento, Lucas Martins; Dorna, Mariana de Souza; Costa, Nara Aline; Okoshi, Katashi; Okoshi, Marina Politi; Azevedo, Paula S.; Polegato, Bertha Furlan; Paiva, Sérgio Alberto Rupp de; Zornoff, Leonardo Antônio Mamede; Minicucci, Marcos F.

doi:10.1016/j.hlc.2021.08.018

Cited by 9 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, myostatin concentrations were low in patients with sarcopenia, and the ROC curve showed that myostatin was the only variable capable of identifying sarcopenia (cutoff value < 2.5 ng/mL, AUC 0.78, sensitivity 0.93, specificity 0.66) [29] . Furthermore, in patients after ST-elevation myocardial infarction, serum myostatin concentrations were positively correlated with muscle mass and muscle strength, and low myostatin was associated with in-hospital mortality, with a cutoff value of<2.20 ng/mL [30] . In that study, multivariate logistic regression showed that high myostatin was associated with lower in-hospital mortality when adjusted for beta blocker use (OR, 0.228; 95 % CI, 0.054–0.974; p = 0.046).…”

Section: Discussionmentioning

confidence: 96%

“…In the present study, the sarcopenia index calculated from GDF-15 and myostatin was a strong regulator of sarcopenia in ROC curve analysis. Recently, some reports showed that myostatin was a biomarker to predict sarcopenia in patients [21] , [29] , [30] . In a previous study that performed ROC curve analysis for myostatin levels, the (log 10 myostatin) / creatine phosphokinase ratio and albumin / myostatin ratio were found to have acceptable diagnostic accuracy in ruling out sarcopenia in all patients with liver cirrhosis [21] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients

Nishikawa

Fukuda

Haruyama

et al. 2022

IJC Heart & Vasculature

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients

Nishikawa

Fukuda

Haruyama

et al. 2022

IJC Heart & Vasculature

View full text Add to dashboard Cite

“…Furthermore, serum myostatin levels were indicative of myocardial damage severity during acute myocardial infarction (AMI), akin to the currently used troponin I peak that estimates infarct size [ 12 ]. A prospective observational study revealed a correlation between lower serum myostatin levels and higher mortality rates among patients hospitalized for myocardial infarction (MI) [ 13 ]. Moreover, in that study, the myostatin concentration was positively linked to muscle mass and strength in patients with ST-segment elevation MI (STEMI) [ 13 ].…”

Section: Myostatinmentioning

confidence: 99%

“…A prospective observational study revealed a correlation between lower serum myostatin levels and higher mortality rates among patients hospitalized for myocardial infarction (MI) [ 13 ]. Moreover, in that study, the myostatin concentration was positively linked to muscle mass and strength in patients with ST-segment elevation MI (STEMI) [ 13 ]. Meanwhile, multiple studies have reported that myostatin levels increase in the hearts and blood of mice 12 h after MI and 10 min after ischemia.…”

Section: Myostatinmentioning

confidence: 99%

Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases

Lyu,

Guo,

Song

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Myokines are a group of cytokines or polypeptides released from skeletal muscle during exercise. Growing evidence suggests that myokines are associated with the development of cardiovascular disease (CVD). Moreover, several myokines in peripheral blood exhibit dynamic changes in different CVD stages. This review summarizes the potential roles of myokines such as myostatin, irisin, brain-derived neurotrophic factor, mitsugumin 53, meteorin-like, and apelin in various CVD, including myocardial infarction, heart failure, atherosclerosis, hypertension, and diabetes. The association of these myokines with biomarkers currently being used in clinical practice is also discussed. Furthermore, the review considers the emerging role of myokines in CVD and addresses the challenges remaining in translating these discoveries into novel clinical biomarkers for CVD.

show abstract

“…Data on the myostatin serum concentration after myocardial infarction are available in humans as well. In a study by Oliveira et al [64], 102 patients with STEMI were included. STEMI was defined as ischemic chest pain with elevation of the ST segment of the electrocardiogram.…”

Section: Myocardial Infarctionmentioning

confidence: 99%

Myostatin and the Heart

Knapp,

Supruniuk,

Górski

2023

Biomolecules

View full text Add to dashboard Cite

Myostatin (growth differentiation factor 8) is a member of the transforming growth factor-β superfamily. It is secreted mostly by skeletal muscles, although small amounts of myostatin are produced by the myocardium and the adipose tissue as well. Myostatin binds to activin IIB membrane receptors to activate the downstream intracellular canonical Smad2/Smad3 pathway, and additionally acts on non-Smad (non-canonical) pathways. Studies on transgenic animals have shown that overexpression of myostatin reduces the heart mass, whereas removal of myostatin has an opposite effect. In this review, we summarize the potential diagnostic and prognostic value of this protein in heart-related conditions. First, in myostatin-null mice the left ventricular internal diameters along with the diastolic and systolic volumes are larger than the respective values in wild-type mice. Myostatin is potentially secreted as part of a negative feedback loop that reduces the effects of the release of growth-promoting factors and energy reprogramming in response to hypertrophic stimuli. On the other hand, both human and animal data indicate that myostatin is involved in the development of the cardiac cachexia and heart fibrosis in the course of chronic heart failure. The understanding of the role of myostatin in such conditions might initiate a development of targeted therapies based on myostatin signaling inhibition.

show abstract

Association Between Serum Myostatin Levels, Hospital Mortality, and Muscle Mass and Strength Following ST-Elevation Myocardial Infarction

Cited by 9 publications

References 27 publications

Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients

Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients

Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases

Myostatin and the Heart

Contact Info

Product

Resources

About